IPR
Topic 117 TRIPS Agreement
Topic 117 — TRIPS Agreement
The TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) is the most comprehensive multilateral IP agreement in history. Negotiated during the Uruguay Round of GATT (1986-1994), it came into effect on 1 January 1995 as Annex 1C to the Marrakesh Agreement Establishing the World Trade Organization. TRIPS revolutionised international IP by integrating it into the WTO trade system, providing for: (1) MINIMUM STANDARDS — members must enact at least specified IP protections; (2) NATIONAL TREATMENT (Article 3) and MOST-FAVOURED-NATION (Article 4); (3) ENFORCEMENT — Members must provide adequate enforcement procedures (civil + criminal + border measures); (4) DISPUTE SETTLEMENT — through WTO's binding dispute settlement mechanism. The 73 articles cover: copyright (Articles 9-14), trademarks (15-21), GIs (22-24), industrial designs (25-26), patents (27-34), layout designs (35-38), trade secrets (39), and anti-competitive practices in licensing (40). The 2001 Doha Declaration affirmed flexibilities — particularly compulsory licensing under Article 31. The 2017 Article 31bis amendment provided permanent solution for compulsory licensing for export. The MC12 Decision (June 2022) clarified COVID vaccines. The 2024 30-year celebration acknowledged TRIPS's evolution from "concession" to "balanced platform". India implemented TRIPS through Patents Amendment Acts 1999, 2002, and 2005 (introducing Section 3(d) and product patents). India has been "Pharmacy of the World" leveraging TRIPS flexibilities. Section 3(d) anti-evergreening, compulsory licensing under Section 84, and parallel imports preserve TRIPS flexibilities. India OPPOSES TRIPS-Plus provisions in bilateral FTAs. This topic walks through every aspect of TRIPS — substantive provisions, enforcement, dispute settlement, India's implementation, and recent developments.
1. TRIPS Foundational Framework
A. Origin and Negotiation
- Negotiated during Uruguay Round of GATT (1986-1994).
- Pushed by developed countries (US, EU, Japan, Switzerland).
- Resisted by developing countries (initial concerns).
- Final text agreed at Marrakesh, April 1994.
- Effective: 1 January 1995.
- Annex 1C to Marrakesh Agreement Establishing WTO.
B. Membership
- 166 WTO members (as of 2024).
- All WTO members bound by TRIPS.
- Universally applicable.
- No selective opt-out (single undertaking principle).
2. Substantive Provisions — IP Areas Covered
A. Copyright (Articles 9-14)
Article | Provision |
|---|---|
Article 9 | Berne Convention obligations + computer programs as literary works. |
Article 10 | Computer programs (literary works) + compilations of data (databases). |
Article 11 | Rental rights for computer programs and films. |
Article 12 | Term of protection (life + 50 years for natural persons; 50 years from publication for legal entities). |
Article 13 | Limitations and exceptions (three-step test). |
Article 14 | Performers, producers of phonograms, broadcasting organizations. |
B. Trade Marks (Articles 15-21)
Article | Provision |
|---|---|
Article 15 | Protectable subject matter: any sign distinguishing goods/services. |
Article 16 | Rights conferred (well-known marks Article 6bis Paris). |
Article 17 | Limited exceptions to trademark rights. |
Article 18 | Term of protection: minimum 7 years renewable; modified to 10 years. |
Article 19 | Use requirement. |
Article 20 | Other requirements limitation. |
Article 21 | Licensing and assignment. |
C. Geographical Indications (Articles 22-24)
Article | Provision |
|---|---|
Article 22 | Protection of geographical indications. |
Article 23 | Additional protection for wines and spirits. |
Article 24 | International negotiations + exceptions. |
D. Industrial Designs (Articles 25-26)
- Article 25 — Requirements for protection (new or original).
- Article 26 — Rights conferred + minimum 10 years.
E. Patents (Articles 27-34)
Article | Provision |
|---|---|
Article 27.1 | Patentable subject matter: products/processes; new + inventive + industrial application. |
Article 27.2 | Public order/morality exception. |
Article 27.3 | Members may exclude: methods of treatment, plants/animals (other than micro-organisms). |
Article 28 | Rights conferred — exclusive making/using/selling/importing. |
Article 29 | Disclosure requirement. |
Article 30 | Limited exceptions. |
Article 31 | Compulsory licensing framework. |
Article 31bis | (2017 amendment) Permanent solution for compulsory licensing for export. |
Article 32 | Revocation/forfeiture review. |
Article 33 | Term of protection: minimum 20 years from filing. |
Article 34 | Process patents — burden of proof. |
F. Other IP Areas (Articles 35-40)
- Articles 35-38 — Layout-Designs (Topographies) of Integrated Circuits.
- Article 39 — Protection of Undisclosed Information (trade secrets).
- Article 40 — Anti-competitive practices in contractual licences.
3. Foundational Principles
A. Article 3 — National Treatment
TRIPS Article 3 — National Treatment "1. Each Member shall accord to the nationals of other Members treatment no less favourable than that it accords to its own nationals with regard to the protection of intellectual property, subject to the exceptions already provided in, respectively, the Paris Convention (1967), the Berne Convention (1971), the Rome Convention or the Treaty on Intellectual Property in Respect of Integrated Circuits. 2. Members may avail themselves of the exceptions permitted under paragraph 1 in relation to judicial and administrative procedures, including the designation of an address for service or the appointment of an agent within the jurisdiction of a Member, only where such exceptions are necessary to secure compliance with laws and regulations which are not inconsistent with the provisions of this Agreement and where such practices are not applied in a manner which would constitute a disguised restriction on trade." |
B. Article 4 — MFN
- Any IP advantage extended to ANY member must be extended to ALL members.
- Limited exceptions — agreements pre-1995, judicial assistance, etc.
- Significant for technology transfer.
C. Article 7 — Objectives
TRIPS Article 7 — Objectives "The protection and enforcement of intellectual property rights should contribute to the promotion of technological innovation and to the transfer and dissemination of technology, to the mutual advantage of producers and users of technological knowledge and in a manner conducive to social and economic welfare, and to a balance of rights and obligations." |
D. Article 8 — Principles
- Article 8.1 — Members may adopt measures to protect public health and nutrition.
- Article 8.2 — Appropriate measures may be needed to prevent abuse of IP rights.
- Foundational for public health flexibilities.
4. Enforcement Provisions (Articles 41-61)
A. General Obligations (Articles 41-42)
- Article 41 — General obligations + accessible procedures.
- Article 42 — Civil judicial procedures + fair process.
- Article 43 — Evidence rules.
- Article 44 — Injunctions.
- Article 45 — Damages.
- Article 46 — Other remedies.
B. Border Measures (Articles 51-60)
- Article 51 — Suspension of release by customs.
- Article 52 — Application by right-holder.
- Article 53 — Security/bond.
- Article 54 — Notification of suspension.
- Article 55 — Duration of suspension.
- Article 56 — Indemnification of importer.
- Article 57 — Right of inspection and information.
- Article 58 — Ex officio action.
- Article 59 — Remedies.
- Article 60 — De minimis imports.
C. Criminal Procedures (Article 61)
- Mandatory criminal procedures + penalties for trademark counterfeiting + commercial-scale copyright piracy.
- Imprisonment + monetary fines + seizure + forfeiture + destruction.
5. Compulsory Licensing — Article 31
✅ Article 31 — Compulsory Licensing Framework Members may grant compulsory licences PROVIDED: (a) Authorization on individual merit basis. (b) Prior unsuccessful efforts to obtain voluntary licence (waived for emergency). (c) Limited scope and duration. (d) Non-exclusive. (e) Non-assignable. (f) Predominantly for domestic market (modified by 31bis). (g) Termination of authorization. (h) Adequate remuneration. (i) Judicial review. (j) Decision review by separate authority. (k) Anti-competitive practices remedies. (l) Semiconductor exclusion (extended uses only). India's implementation: · Section 84 Patents Act — three grounds (reasonable requirements + affordability + working). · Section 92 — government use for public emergency. · Section 100 — government use without licence. · Bayer v. Natco 2012 — first and only successful application. |
6. Article 31bis — Permanent Solution (2017)
A. The 2017 Amendment
- Adopted by WTO General Council 23 January 2017.
- First-ever amendment to a WTO trade agreement.
- Permanent solution to August 2003 Decision.
B. The Provision
✅ Article 31bis — Compulsory Licensing for Export Allows compulsory licences specifically for EXPORT to other countries with insufficient or no manufacturing capacity. Key features: · Permits export of compulsory-licensed products. · Eligible countries — least-developed and certain developing countries. · Notification requirements. · Quality and quantity requirements. · Specific labeling. Significance: · Permanent multilateral solution for access to medicines. · Enables global response to public health emergencies. · Addresses limitations of Article 31(f) "predominantly for domestic market". |
7. Doha Declaration 2001
📖 Doha Declaration on TRIPS Agreement and Public Health, 14 November 2001 (WT/MIN(01)/DEC/2) Background — Adopted at Fourth Ministerial Conference, Doha, Qatar (9-14 November 2001). Driven by HIV/AIDS crisis in Sub-Saharan Africa. Key Affirmations: (i) "TRIPS Agreement does not and should not prevent Members from taking measures to protect public health." (ii) Recognition of "gravity of public health problems afflicting many developing and least-developed countries, especially those resulting from HIV/AIDS, tuberculosis, malaria and other epidemics." (iii) Confirmed flexibilities including: · Compulsory licensing. · Parallel imports. · Public health emergencies. · National definition of grounds for compulsory licences. (iv) Affirmed objectives + principles in Articles 7 + 8 TRIPS. Specific Items: · LDC pharmaceutical patent transition extended to 2016 (later extended further). · Issue of compulsory licensing for countries with insufficient manufacturing capacity flagged for resolution. Significance — FOUNDATIONAL public health declaration: · India lead role in negotiations. · Reaffirmed TRIPS flexibilities. · Foundation for Indian Section 3(d), Section 84. · Watershed for international IP framework. · Continued influence on policy. |
8. India's TRIPS Implementation
A. Three-Stage Implementation
Stage | Year | Implementation |
|---|---|---|
Stage 1 | 1999 | Patents (Amendment) Act 1999 — pipeline product patents (mailbox + EMR). |
Stage 2 | 2002 | Patents (Amendment) Act 2002 — substantive amendments including 20-year term, opposition. |
Stage 3 | 2005 | Patents (Amendment) Act 2005 — full TRIPS compliance; product patents for pharmaceuticals + agro-chemicals; Section 3(d) introduced. |
B. India's TRIPS Flexibilities Adopted
- Section 3(d) — anti-evergreening (only therapeutic efficacy enhancement patentable).
- Section 84 — compulsory licensing on grounds.
- Section 92 — government use for public emergency.
- Section 100 — government use without licence.
- Section 47 — research/private use exception.
- Section 107 — Bolar exception (research for regulatory approval).
- Sections 25 + 64 — pre-grant + post-grant opposition.
- Section 8 — disclosure of foreign filing.
C. India's TRIPS Cases
Case | TRIPS Issue |
|---|---|
India — Patent Protection (US complaint, 1997) | Mailbox + EMR; India compliance affirmed. |
India — Patent Protection (EU complaint, 1998) | Similar issues; India compliance affirmed. |
Novartis v. UoI (SC 2013) | Section 3(d) within TRIPS Article 27. |
Bayer v. Natco (Patent Office 2012) | Section 84 within TRIPS Article 31. |
9. MC12 Decision (June 2022)
✅ MC12 Decision on COVID-19 Vaccines Background: · COVID-19 pandemic 2020-2022. · Global vaccine inequity. · India + South Africa proposal for TRIPS waiver (October 2020). MC12 Decision (17 June 2022): · Limited scope clarification. · Focused on COVID-19 vaccine production and supply. · Procedural simplifications for compulsory licensing. · 5-year duration. Subsequent Discussions (2022-2024): · Extension to therapeutics + diagnostics debated. · February 2024 — TRIPS Council could not reach consensus on extension. · Continuing dialogue. India's Role: · Co-leader with South Africa in waiver proposal. · Strong advocacy for vaccine access. · Public health flexibility approach. Significance: · Demonstrates ongoing relevance of TRIPS flexibilities. · Pandemic response precedent. · Continued policy debate. |
10. Recent TRIPS Developments
Development | Year | Significance |
|---|---|---|
Article 31bis adoption | 23 January 2017 | Permanent solution for compulsory licensing for export. |
MC12 Decision (COVID vaccines) | 17 June 2022 | Limited COVID vaccines clarification. |
TRIPS Council COVID extension dialogue | 2022-2024 | Therapeutic/diagnostic extension debated. |
30 Years TRIPS | April 2024 | WTO high-level dialogue. |
WIPO Treaty IP/Genetic Resources/Traditional Knowledge | May 2024 | New international framework. |
🎯 EXAM POINTERS — TOPIC 117
|